OpenLB
Open Library of Bioscience
Advanced Search
Vaccine
Apr 25, 2014;32 (20): 2364-74.

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

Richard N Greenberg, Alejandra Gurtman, Robert W Frenck, Cynthia Strout, Kathrin U Jansen, James Trammel, Daniel A Scott, Emilio A Emini, William C Gruber, Beate Schmoele-Thoma
Author Information
  1. Richard N Greenberg: University of Kentucky School of Medicine, Department of Medicine, Room MN-663, 800 Rose Street, Lexington, KY 40536-0084, United States. Electronic address: rngree01@uky.edu.
  2. Alejandra Gurtman: Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, United States. Electronic address: alejandra.gurtman@pfizer.com.
  3. Robert W Frenck: Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 6014, Cincinnati, OH, United States. Electronic address: robert.frenck@cchmc.org.
  4. Cynthia Strout: Coastal Carolina Research Center, 1156 Bowman Road, Suite 102, Mount Pleasant, SC, United States. Electronic address: cstrout@coastalcarolinaresearch.com.
  5. Kathrin U Jansen: Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, United States. Electronic address: kathrin.jansen@pfizer.com.
  6. James Trammel: inVentiv Health Clinical, LLC, 504 Carnegie Center, Princeton, NJ, United States. Electronic address: james.trammel@inventivhealth.com.
  7. Daniel A Scott: Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, United States. Electronic address: dan.scott@pfizer.com.
  8. Emilio A Emini: Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, United States. Electronic address: emilio.emini@pfizer.com.
  9. William C Gruber: Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, United States. Electronic address: bill.gruber@pfizer.com.
  10. Beate Schmoele-Thoma: Pfizer Vaccines Research, Pfizer Pharma GmbH, Linkstrasse 10, 10785 Berlin, Germany. Electronic address: beate.schmoele-thoma@pfizer.com.
PMID: 24606865 DOI: 10.1016/j.vaccine.2014.02.002

Abstract

BACKGROUND: Unlike free pneumococcal polysaccharide vaccines (PPSVs), pneumococcal conjugate vaccines (PCVs) induce a T-cell-dependent immune response. The study assessed potential influence of initial 13-valent PCV (PCV13) or 23-valent PPSV (PPSV23) on subsequent vaccine administrations.
METHODS: We conducted a randomized, modified double-blind study in 720 pneumococcal vaccine-naïve adults 60-64 years of age. Subjects received either PCV13 at year 0 and PCV13 at year 1; PCV13 at year 0 and PPSV23 at year 1; or PPSV23 at year 0 and PCV13 at year 1. Antipneumococcal opsonophagocytic activity (OPA) titers were measured before and 1 month after each vaccination.
RESULTS: OPA titers following PPSV23 given 1 year after PCV13 (PCV13/PPSV23) (a) were noninferior for the 12 common serotypes and significantly higher for 6 of 12 common serotypes than those following only an initial PPSV23; and (b) were significantly higher for 11 of 12 common serotypes compared with PPSV23 followed by PCV13 (PPSV23/PCV13). In addition, PPSV23 followed 1 year later by PCV13 (PPSV23/PCV13) elicited significantly lower OPA titers than after only an initial dose of PCV13 for all 13 serotypes. Responses after a second vaccination with either PCV13 (PCV13/PCV13) or PPSV23 (PCV13/PPSV23) were noninferior for 9 of 13 and 8 of 12 common serotypes compared with the initial PCV13 dose.
CONCLUSION: In pneumococcal vaccine-naïve adults 60-64 years of age, an initial PCV13 augmented the antipneumococcal response to subsequent administration of PPSV23 for many of the serotypes in common to both vaccines. In contrast, an initial PPSV23 resulted in a diminished response to subsequent administration of PCV13 for all serotypes. With a relatively short 1-year interval between doses, responses after a second vaccination with PCV13 (PCV13/PCV13) or PPSV23 (PCV13/PPSV23) were noninferior for a majority of serotypes compared with the initial PCV13 dose, probably reflecting the need for a longer interval between vaccine administrations. ClinicalTrials.gov Identifier: NCT00574548.

Keywords

Adult Pneumococcal conjugate vaccine Recall responses

Associated Data

ClinicalTrials.gov | NCT00574548

Grants

  1. P30AG028383/NIA NIH HHS

MeSH Term

Double-Blind Method
Female
Humans
Immunization Schedule
Male
Middle Aged
Phagocytosis
Pneumococcal Infections
Pneumococcal Vaccines
Streptococcus pneumoniae
Vaccines, Conjugate

Chemicals

13-valent pneumococcal vaccine
23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal Vaccines
Vaccines, Conjugate
Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0PCV13PPSV23yearserotypespneumococcalinitial1vaccinecommon12vaccinesconjugateresponsesubsequentvaccine-naïveadults60-64yearsage0OPAtitersvaccinationPCV13/PPSV23noninferiorsignificantlycompareddoseadministrationpolysaccharidestudy13-valent23-valentadministrationseitherfollowinghigherfollowedPPSV23/PCV1313secondPCV13/PCV13intervalresponsesBACKGROUND:UnlikefreePPSVsPCVsinduceT-cell-dependentimmuneassessedpotentialinfluencePCVPPSVMETHODS:conductedrandomizedmodifieddouble-blind720SubjectsreceivedAntipneumococcalopsonophagocyticactivitymeasuredmonthRESULTS:given6b11additionlaterelicitedlowerResponses98CONCLUSION:augmentedantipneumococcalmanycontrastresulteddiminishedrelativelyshort1-yeardosesmajorityprobablyreflectingneedlongerClinicalTrialsgovIdentifier:NCT00574548SequentialAdultPneumococcalRecall

Similar Articles

Cited By (62)

Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.Current Recommendations for Pneumococcal Vaccination of Children and Adults.Pneumococcal Conjugate Vaccine Safety in Elderly Adults.Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.Onset of Frozen Shoulder Following Pneumococcal and Influenza Vaccinations.Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.Mortality burden associated with all-cause pneumonia among adults with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignancies: a population-based comparative study for informed decision-making in public health policies.A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014.
See all "Cited by" articles